Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.

Lan-Lan PangJia-Di GanJia-Rong TanYi-Hua HuangJun LiaoWei-Ting LiangPeng-Bo DengWen-Feng Fang

Published in: Cancer (2022)

The present study elucidated the differential benefits of afatinib within different mutation genotypes and first revealed the spectrum of potential resistance mechanisms in patients with EGFR G719X/L861Q/S768I. The results of this study may provide practical clinical information that can guide optimal treatment in this setting.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
small cell lung cancer
healthcare
single cell
health information
replacement therapy
smoking cessation